Efficacy and outcomes of [ 177 Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent…

Cohort studyEuropean journal of nuclear medicine and molecular imaging· Jul 2026

Efficacy and outcomes of [ 177 Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent ARPI: a real-world single-center analysis.

Martin Rust, David Ventura, Clemens Backhaus … Kambiz Rahbar

Nuclear MedicineCohort studyTreatmentQ1IF 5.8

Concurrent androgen receptor pathway inhibitor therapy not associated with better survival, real-world study

Efficacy and outcomes of [ 177 Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent ARPI: a real-world single-center analysis.

Martin Rust … Kambiz Rahbar

European journal of nuclear medicine and molecular imaging · Jul 2026 · Q1 in Radiology

Purpose

This study evaluated outcomes of [ 177 Lu]Lu-PSMA-617 with or without concurrent Androgen Receptor Pathway Inhibitors (Androgen Receptor Pathway Inhibitors) in a real-world setting.

Methods

We retrospectively analyzed electronic health records of mCRPC patients treated with [ 177 Lu]Lu-PSMA-617 in routine clinical practice between June 2023 and August 2024.

n = 108 patients

Results

adding a pathway inhibitor did not lower death risk, even a slight uptick

12.7months

Monotherapy

13.5months

Concurrent ARPI

More results

Among 108 patients, 65 received [ 177 Lu]Lu-PSMA-617 monotherapy and 43 concurrent Androgen Receptor Pathway Inhibitors therapy.

Baseline characteristics were generally well balanced, with slightly higher hemoglobin and a trend toward lower PSA in the Androgen Receptor Pathway Inhibitors group.

“

Conclusion · 1 of 2

In this real-world cohort of Androgen Receptor Pathway Inhibitors- and taxane-pretreated mCRPC patients, concurrent Androgen Receptor Pathway Inhibitors use during [ 177 Lu]Lu-PSMA-617 was not independently associated with improved clinical outcomes.

Conclusion · 2 of 2

These exploratory findings do not provide evidence to support routine continuation of Androgen Receptor Pathway Inhibitors beyond progression at the time of radioligand therapy initiation.

Efficacy and outcomes of [ 177 Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent ARPI: a real-world single-center analysis.

Efficacy and outcomes of [ 177 Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent ARPI: a real-world single-center analysis.

Related papers